neurofilament medium chainGenealiases: NEF3 · NF-M · NFM
Q-omics provides the consensus-scored NEFM profile across patient tissues and cancer cell-line models. NEFM expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NEFM is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, NEFM protein abundance shows 20,531 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, COAD, and GBM as cancer lineages where NEFM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEFM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEFM survival associations across molecular data types. NEFM RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEFM RNA expression–survival associations across cancer types. High NEFM expression shows unfavorable associations in HNSC, STAD, LIHC and LUSC, but favorable associations in UCEC and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for NEFM RNA expression.
This table summarizes NEFM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NEFM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEFM shows lower tumor expression in COAD, KICH, KIRC, READ and STAD and higher tumor expression in HNSC. The COAD box plot shows higher NEFM RNA expression in normal versus tumor tissue (log2 FC = −0.908, t-test p < 0.001).
This table shows molecular features associated with NEFM in patient tissues and cancer cell lines. In patient samples, NEFM shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NEFM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
